A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. Issue 5 (3rd May 2020)

• Record Type: Journal Article
• Authors: Bellinato, Francesco; Gisondi, Paolo; Girolomoni, Giampiero
• Is Part Of: Expert review of clinical pharmacology. Volume 13:Issue 5(2020)
• Page Start: 481
• Page End: 491
• Publication Date: 2020-05-03
• Subjects: Psoriatic arthritis -- psoriasis -- pharmacological treatment -- biologics -- small molecules; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2020.1759415
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis in 20-30% of patients. PsA presents as a heterogeneous disease involving different domains and burdened by an important impact on function and quality of life. Areas covered: Dermatologists play an important role in the early detection of PsA because in most patients PsA develop after cutaneous psoriasis. The ideal goal of treating patients with PsA is to optimize the controls of symptoms, improve quality of life, and prevent structural damage and disability. The choice of treatment in patients with PsA should take into account also the skin signs and symptoms. Treatment options include NSAIDs, synthetic DMARDSs, anti-TNF-α agents, anti-IL-12/IL-23 agents, anti-IL-17 agents, PDE4 inhibitors, JAK inhibitors, and co-stimulatory blockers. A narrative review based on electronic searches on PubMed® database was performed. Original articles assessing either the role of the dermatologist in the management of PsA and the available treatments for PsA were included. Expert opinion: Among different treatments, some drugs show more efficacy in joint signs and symptoms, and poor response on the skin and vice versa. The perspective of the dermatologist in a multidisciplinary setting may provide a helpful tool in the management of patients with PsA.